project . 2015 - 2020 . Closed

MyNano

Towards the design of Personalised Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 648831 Call for proposal: ERC-2014-CoG
  • Funded under: H2020 | ERC | ERC-COG Overall Budget: 1,724,170 EURFunder Contribution: 1,724,170 EUR
  • Status: Closed
  • Start Date
    01 Jul 2015
    End Date
    31 Dec 2020
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted combination therapies, concept I pioneered that allows enhanced therapeutic efficiency. Early clinical trials involving conjugates showed activity in chemotherapy refractory patients and reduced drug-related toxicity. However, there is a growing concern on patient variability regarding tumor patho-physiology that underlie successful therapeutic outcome. Specific biomarkers are required to select those patients most likely to show good clini...
Partners
Description
Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted combination therapies, concept I pioneered that allows enhanced therapeutic efficiency. Early clinical trials involving conjugates showed activity in chemotherapy refractory patients and reduced drug-related toxicity. However, there is a growing concern on patient variability regarding tumor patho-physiology that underlie successful therapeutic outcome. Specific biomarkers are required to select those patients most likely to show good clini...
Partners
Any information missing or wrong?Report an Issue